Sarepta Therapeutics | SRPT - Debt


Sarepta Therapeutics reported $1.04B in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Capricor Therapeutics USD 3.38M 0 Mar/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
Incyte USD 39.43M 982K Mar/2026
Insmed USD 727.62M 275K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Moderna USD 1.31B 571M Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.33B 1.43B Dec/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026